Also thought I would look at their European Patent. It appears they only sought patents in US, EU, and JP.
One of the biggest knocks on the US system is that you can file endless continuation applications, which are all the same application, but with different claims (sometimes to markedly different subject matter, sometimes not). Regardless, continuations themselves do not extend patent term, they all expire on the same day, 20 years from filing of the first application. In a lot of senses, a "family" of continuation patents can be regarded as one big patent.
The EU and most other jurisdictions don't allow that. But Abbott let the first European Patent application, corresponding to the above, die on the vine, and have filed a "divisional." A divisional is allowed when an Office tells you you are claiming more than one invention in an application, that is, you have claims to a composition, a dosage, etc. Each would be regarded as a different invention and you have to file a second, third, etc. to seek the other types of claims/inventions identified.
So, shenanigans have ensued. The biggest booger in the US is the Patent Term Restoration act, which treats drugs and devices subject to approval differently than everything else. The maximum attainable term is supposed to be 14 years from approval.